Barclays PLC Purchases Shares of 105,766 Clover Health Investments, Corp. (NASDAQ:CLOV)

Barclays PLC acquired a new stake in shares of Clover Health Investments, Corp. (NASDAQ:CLOV) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 105,766 shares of the company’s stock, valued at approximately $298,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of CLOV. Concurrent Investment Advisors LLC bought a new stake in shares of Clover Health Investments during the third quarter valued at approximately $28,000. Sigma Planning Corp bought a new stake in shares of Clover Health Investments during the third quarter valued at approximately $29,000. Parallax Volatility Advisers L.P. bought a new stake in shares of Clover Health Investments during the third quarter valued at approximately $38,000. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Clover Health Investments by 54.4% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 34,372 shares of the company’s stock valued at $42,000 after acquiring an additional 12,104 shares in the last quarter. Finally, Realta Investment Advisors bought a new stake in shares of Clover Health Investments during the third quarter valued at approximately $44,000. Institutional investors own 19.77% of the company’s stock.

Clover Health Investments Trading Up 5.1 %

Shares of Clover Health Investments stock opened at $3.29 on Monday. The stock has a fifty day simple moving average of $3.42 and a 200 day simple moving average of $2.84. Clover Health Investments, Corp. has a 12-month low of $0.61 and a 12-month high of $4.71. The company has a market capitalization of $1.65 billion, a P/E ratio of -16.45 and a beta of 1.95.

Clover Health Investments (NASDAQ:CLOV) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. Clover Health Investments had a negative return on equity of 25.46% and a negative net margin of 5.92%. The business had revenue of $330.99 million during the quarter, compared to the consensus estimate of $347.60 million. During the same quarter in the prior year, the company posted ($0.09) earnings per share. On average, analysts predict that Clover Health Investments, Corp. will post -0.12 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on CLOV. UBS Group began coverage on Clover Health Investments in a report on Monday, October 7th. They set a “neutral” rating and a $4.00 price objective for the company. Craig Hallum began coverage on Clover Health Investments in a report on Tuesday, December 17th. They set a “buy” rating and a $6.00 price target for the company.

Clover Health Investments Company Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.